Irsamla

Vortioxetine Hydrobromide, the active ingredient in Irsamla, is a serotonin modulator and stimulator presented as a tablet for oral use. It is prescribed to treat major depressive disorder in adult patients.

GNH USA supplies Irsamla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets EU quality standards and is manufactured under strict Good Manufacturing Practice guidelines. Our distribution network ensures reliable delivery to diverse healthcare settings.

Vortioxetine Hydrobromide is indicated for the treatment of major depressive disorder, a condition characterized by persistent low mood and loss of interest.

Major depressive disorder (acute): reduces depressive symptoms and improves mood. Major depressive disorder (maintenance): helps prevent relapse of depressive episodes. Major depressive disorder (cognitive symptoms): enhances concentration and cognitive function.

Vortioxetine Hydrobromide may cause a range of adverse reactions, some of which are common and others that are serious or rare.

Common Side Effects: - Nausea - Headache - Dizziness - Constipation

Serious or Rare Side Effects: - Serotonin syndrome (potentially life‑threatening) - Emergence of suicidal thoughts or behaviors - Severe allergic reaction such as anaphylaxis

When prescribing Vortioxetine Hydrobromide, clinicians should consider several safety aspects.

Pregnancy: safety not established; use only if potential benefit justifies the risk. Breastfeeding: unknown excretion; weigh maternal benefit against infant risk. Renal impairment: dose adjustment may be required; monitor renal function. Hepatic impairment: assess liver function and consider dose modification. Concomitant serotonergic agents: increased risk of serotonin syndrome; monitor closely. Store at room temperature: keep in original container, protect from moisture and light.

Vortioxetine Hydrobromide can interact with other medicines, necessitating careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Other serotonergic antidepressants (e.g., SSRIs, SNRIs): avoid concurrent use. - Triptans: may precipitate serotonin syndrome.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may increase bleeding risk. - Strong CYP2D6 inhibitors (e.g., fluoxetine): may raise vortioxetine plasma levels.